Share on StockTwits

Valeant Pharmaceuticals Intl (NYSE:VRX) was downgraded by Zacks from an “outperform” rating to an “underperform” rating in a research report issued to clients and investors on Wednesday. They currently have a $101.00 price target on the stock. Zacks‘s price objective would indicate a potential downside of 8.20% from the company’s current price.

Valeant Pharmaceuticals Intl (NYSE:VRX) traded down 0.58% during mid-day trading on Wednesday, hitting $110.02. The stock had a trading volume of 3,925,751 shares. Valeant Pharmaceuticals Intl has a 52 week low of $95.28 and a 52 week high of $153.10. The stock has a 50-day moving average of $122.0 and a 200-day moving average of $130.5. The company’s market cap is $36.902 billion.

Valeant Pharmaceuticals Intl (NYSE:VRX) last issued its quarterly earnings data on Thursday, July 31st. The company reported $1.91 earnings per share for the quarter, meeting the analysts’ consensus estimate of $1.91. The company had revenue of $1.99 billion for the quarter, compared to the consensus estimate of $1.06 billion. During the same quarter last year, the company posted $1.34 earnings per share. Valeant Pharmaceuticals Intl’s revenue was up 86.2% compared to the same quarter last year. On average, analysts predict that Valeant Pharmaceuticals Intl will post $8.02 earnings per share for the current fiscal year.

A number of other firms have also recently commented on VRX. Analysts at Susquehanna cut their price target on shares of Valeant Pharmaceuticals Intl to $160.00 in a research note on Friday, August 1st. Separately, analysts at Piper Jaffray cut their price target on shares of Valeant Pharmaceuticals Intl from $151.00 to $135.00 in a research note on Friday, August 1st. Finally, analysts at CIBC cut their price target on shares of Valeant Pharmaceuticals Intl from $160.00 to $155.00 in a research note on Friday, August 1st. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. Valeant Pharmaceuticals Intl currently has an average rating of “Buy” and a consensus price target of $148.00.

Valeant Pharmaceuticals International, Inc, formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products.

To view Zacks’ full report, visit Zacks’ official website.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.